Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03403049 · ClinicalTrials.gov registry record · Phase 1
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
A Phase 1 study of Cancer and Pancreatic Cancer, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT03403049 is a Phase 1 study of Cancer and Pancreatic Cancer that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 14 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03403049, a Phase 1 study of Cancer and Pancreatic Cancer, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase I trial to determine the maximum tolerated dose of carbon ion radiotherapy for the treatment of locally advanced, unresectable, pancreatic cancer.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Gemcitabine + Cisplatin
- RADIATION Carbon Ion
- DRUG Gemcitabine + Capecitabine
- DRUG Gemcitabine + Erlotinib
Study Locations (2)
New York
- Albert Einstein College of Medicine - The Bronx
Shanghai Municipality
- Shanghai Proton and Heavy Ion Center - Shanghai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-04-01 |
| Est. Completion | 2019-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03403049
The ClinicalTrials.gov registry entry for NCT03403049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine is the first listed.
NCT03403049 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Shanghai Municipality.
Frequently Asked Questions
What is clinical trial NCT03403049 about?
NCT03403049 is a clinical study titled "Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer". This is a phase I trial to determine the maximum tolerated dose of carbon ion radiotherapy for the treatment of locally advanced, unresectable, pancreatic cancer.
What is the current status of trial NCT03403049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2016-04-01. Estimated completion is 2019-07-09.
What conditions does trial NCT03403049 study?
This clinical trial studies the following conditions: Cancer, Pancreatic Cancer.
What interventions are being tested in trial NCT03403049?
The interventions under investigation include: Gemcitabine (DRUG), Gemcitabine + Cisplatin (DRUG), Carbon Ion (RADIATION), Gemcitabine + Capecitabine (DRUG), Gemcitabine + Erlotinib (DRUG).
Who is sponsoring clinical trial NCT03403049?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03403049 being conducted?
This trial has 2 study locations across New York, Shanghai Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.